FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Barry Gertz

Research Profile

Procedures

Chemicals & Drugs

Concepts & Ideas

Disorders

Osteoporosis, Postmenopausal

Physiology

Drug Interactions

Co-author Network

Publications

TOP 3
Jules I Schwartz; Chau Thach; Kenneth C Lasseter; Jutta Miller; David Hreniuk; Deborah Hilliard; Karen Snyder; Barry J Gertz; Keith M Gottesdiener
Effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs on urinary sodium excretion, blood pressure, and other renal function indicators in elderly subjects consuming a controlled sodium diet.
E Gineyts; J A Mo; A Ko; D B Henriksen; Sean P Curtis; Barry J Gertz; Patrick Garnero; Pierre D Delmas
Effects of ibuprofen on molecular markers of cartilage and synovium turnover in patients with knee osteoarthritis.
Matthew R Weir; Rhoda S Sperling; Alise S Reicin; Barry J Gertz
Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Barry Gertz (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2007: Jules I Schwartz; Chau Thach; Kenneth C Lasseter; Jutta Miller; David Hreniuk; Deborah Hilliard; Karen Snyder; Barry J Gertz; Keith M Gottesdiener
Effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs on urinary sodium excretion, blood pressure, and other renal function indicators in elderly subjects consuming a controlled sodium diet.
Journal of clinical pharmacology 2007;47(12):1521-31.
2004: E Gineyts; J A Mo; A Ko; D B Henriksen; Sean P Curtis; Barry J Gertz; Patrick Garnero; Pierre D Delmas
Effects of ibuprofen on molecular markers of cartilage and synovium turnover in patients with knee osteoarthritis.
Annals of the rheumatic diseases 2004;63(7):857-61.
2003: Matthew R Weir; Rhoda S Sperling; Alise S Reicin; Barry J Gertz
Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program.
American heart journal 2003;146(4):591-604.
2003: Keith M Gottesdiener; Nancy Agrawal; Arturo G Porras; Peggy Wong; J Douglas Rogers; Barry J Gertz; Jan S Redfern; Thomas C Marbury
Effects of renal insufficiency and hemodialysis on the pharmacokinetics of rofecoxib.
American journal of therapeutics 2003;10(4):252-8.
2003: aimee dallob; Christopher J Hawkey; Howard Greenberg; Nicholas Wight; Paul De Schepper; Scott Waldman; Peggy Wong; Lisa DeTora; Barry J Gertz; Nancy Agrawal; John Wagner; Keith M Gottesdiener
Characterization of etoricoxib, a novel, selective COX-2 inhibitor.
Journal of clinical pharmacology 2003;43(6):573-85.
2003: Nathaniel Katz; William D Ju; David Krupa; Rhoda S Sperling; Diana Bozalis Rodgers; Barry J Gertz; Joseph Gimbel; Spencer Coleman; Chester Fisher; Shahriar Nabizadeh; David Borenstein
Efficacy and safety of rofecoxib in patients with chronic low back pain: results from two 4-week, randomized, placebo-controlled, parallel-group, double-blind trials.
Spine 2003;28(9):851-8; discussion 859.
2003: Jules I Schwartz; Saurabh Mukhopadhyay; Arturo G Porras; Kala-Jyoti Viswanathan-Aiyer; Sherilyn Adcock; David L Ebel; Barry J Gertz
Effect of rofecoxib on prednisolone and prednisone pharmacokinetics in healthy subjects.
Journal of clinical pharmacology 2003;43(2):187-92.
2003: Jules I Schwartz; Patrick J Larson; Arturo G Porras; Kala-Jyoti Viswanathan-Aiyer; Nancy G B Agrawal; Kenneth C Lasseter; Ralph S Mazenko; Sheila A Merschman; Barry J Gertz
Pharmacokinetic evaluation of rofecoxib : comparison of tablet and suspension formulations.
Clinical drug investigation 2003;23(8):503-9.
2002: Keith M Gottesdiener; Thomas J Schnitzer; C Fisher; B Bockow; J Markenson; A Ko; Lisa DeTora; S Curtis; LA Geissler; Barry J Gertz
Results of a randomized, dose-ranging trial of etoricoxib in patients with osteoarthritis.
Rheumatology (Oxford, England) 2002;41(9):1052-61.
2002: Alan K. Matsumoto; Agustin Melian; David R Mandel; Harris H McIlwain; David Borenstein; Peng Liang Zhao; Christopher R Lines; Barry J Gertz; Sean Curtis
A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis.
The Journal of rheumatology 2002;29(8):1623-30.
2002: Jules I Schwartz; K Vandormael; M P Malice; R N Kalyani; Kenneth C Lasseter; G B Holmes; Barry J Gertz; Keith M Gottesdiener; M Laurenzi; K-J Redfern; K Brune
Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet.
Clinical pharmacology and therapeutics 2002;72(1):50-61.
2002: Simon Van Belle; Michael R Lichinitser; Rudolph M Navari; August M Garin; Marc L A Decramer; Alain Riviere; Myo Thant; Elmer Brestan; Binh Bui; Krista Eldridge; Marina De Smet; Nicole Michiels; Rick R Reinhardt; Alexandra D Carides; Judith K Evans; Barry J Gertz
Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869.
Cancer 2002;94(11):3032-41.
2002: Eduardo Collantes; Sean P Curtis; Ka Wing Lee; Noemi Casas; Timothy McCarthy; Agustin Melian; Peng L Zhao; Diana B Rodgers; Calogera L McCormick; Michael Lee; Christopher R Lines; Barry J Gertz
A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis [ISRCTN25142273].
BMC family practice 2002;3():10.
2002: Terry P Combs; John A Wagner; Joel P Berger; Thomas W Doebber; Wen-Jun Wang; Bei B Zhang; Michael Tanen; Anders H Berg; Stephen O'Rahilly; David B Savage; Krishna Chatterjee; Stuart Weiss; Patrick J Larson; Keith M Gottesdiener; Barry J Gertz; Maureen J Charron; Philipp E Scherer; David E Moller
Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: a potential mechanism of insulin sensitization.
Endocrinology 2002;143(3):998-1007.
2002: Jules I Schwartz; Peggy H Wong; Arturo G Porras; David L Ebel; Thomas R Hunt; Barry J Gertz
Effect of rofecoxib on the pharmacokinetics of chronically administered oral contraceptives in healthy female volunteers.
Journal of clinical pharmacology 2002;42(2):215-21.
2002: Barry J Gertz; David Krupa; James A Bolognese; Rhoda S Sperling; Alise S Reicin
A comparison of adverse renovascular experiences among osteoarthritis patients treated with rofecoxib and comparator non-selective non-steroidal anti-inflammatory agents.
Current medical research and opinion 2002;18(2):82-91.
2001: Marvin A Konstam; Matthew R Weir; Alise S Reicin; Deborah Shapiro; Rhoda S Sperling; Eliav Barr; Barry J Gertz
Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib.
Circulation 2001;104(19):2280-8.
2001: Jules I Schwartz; Nancy G B Agrawal; Peggy H Wong; Kenneth Bachmann; Arturo G Porras; Jutta L Miller; David L Ebel; Marshall Sack; G B Holmes; Jan S Redfern; Barry J Gertz
Lack of pharmacokinetic interaction between rofecoxib and methotrexate in rheumatoid arthritis patients.
Journal of clinical pharmacology 2001;41(10):1120-30.
2001: Ethel Codner; Fernando Cassorla; Anatoly Tiulpakov; M Verónica Mericq; Alejandra Avila; Ora Hirsch Pescovitz; Johan Svensson; KA Cerchio; David Krupa; Barry J Gertz; G Murphy
Effects of oral administration of ibutamoren mesylate, a nonpeptide growth hormone secretagogue, on the growth hormone-insulin-like growth factor I axis in growth hormone-deficient children.
Clinical pharmacology and therapeutics 2001;70(1):91-8.
2001: Veronique Cocquyt; Simon Van Belle; Rick R Reinhardt; M L Decramer; M O'Brien; J H Schellens; M Borms; L Verbeke; F Van Aelst; Marina De Smet; Alexandra D Carides; Krista Eldridge; Barry J Gertz
Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis.
European journal of cancer (Oxford, England : 1990) 2001;37(7):835-42.
2001: D Campos; J R Pereira; Rick R Reinhardt; C Carracedo; S Poli; C Vogel; J Martinez-Cedillo; A Erazo; JM Wittreich; L O Eriksson; Alexandra D Carides; Barry J Gertz
Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(6):1759-67.
2001: MG Murphy; S Weiss; Michael R McClung; Thomas J Schnitzer; KA Cerchio; J Connor; David Krupa; Barry J Gertz
Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.
The Journal of clinical endocrinology and metabolism 2001;86(3):1116-25.
2001: Nicholas Wight; Keith M Gottesdiener; N M Garlick; Clare Atherton; S Novak; Barry J Gertz; N A Calder; Josee Cote; Peggy Wong; aimee dallob; Christopher J Hawkey
Rofecoxib, a COX-2 inhibitor, does not inhibit human gastric mucosal prostaglandin production.
Gastroenterology 2001;120(4):867-73.
2001: Jules I Schwartz; M De Smet; Patrick J Larson; Rene Verbesselt; David L Ebel; R Lins; S Lens; Arturo G Porras; Barry J Gertz
Effect of rofecoxib on the pharmacokinetics of digoxin in healthy volunteers.
Journal of clinical pharmacology 2001;41(1):107-12.
2000: Jules I Schwartz; K J Bugianesi; David L Ebel; M De Smet; R Haesen; Patrick J Larson; A Ko; Rene Verbesselt; Thomas L Hunt; R Lins; S Lens; Arturo G Porras; J Dieck; Bart Keymeulen; Barry J Gertz
The effect of rofecoxib on the pharmacodynamics and pharmcokinetics of warfarin.
Clinical pharmacology and therapeutics 2000;68(6):626-36.
2000: Anne Van Hecken; Jules I Schwartz; M Depré; Inge De Lepeleire; aimee dallob; Wesley Tanaka; K Wynants; A Buntinx; Jef Arnout; Peggy H Wong; David L Ebel; Barry J Gertz; Paul De Schepper
Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers.
Journal of clinical pharmacology 2000;40(10):1109-20.
2000: M Depré; Elliot W Ehrich; Anne Van Hecken; Inge De Lepeleire; aimee dallob; Peggy Wong; Arturo G Porras; Barry J Gertz; Paul De Schepper
Pharmacokinetics, COX-2 specificity, and tolerability of supratherapeutic doses of rofecoxib in humans.
European journal of clinical pharmacology 2000;56(2):167-74.
2000: Sean P Curtis; I Eardley; M Boyce; Patrick Larson; R Haesen; Keith M Gottesdiener; Barry J Gertz
Single dose methodology to assess the influence of an alpha1-adrenoceptor antagonist on uroflowmetric parameters in patients with benign prostatic hyperplasia.
British journal of clinical pharmacology 2000;49(3):269-73.
1999: Jacqueline B McCrea; Thomayant Prueksaritanont; Barry J Gertz; Alexandra D Carides; Lisa P Gillen; S Antonello; MJ Brucker; Cynthia Miller-Stein; B Osborne; Scott Waldman
Concurrent administration of the erythromycin breath test (EBT) and oral midazolam as in vivo probes for CYP3A activity.
Journal of clinical pharmacology 1999;39(12):1212-20.
1999: Elliot W Ehrich; Thomas J Schnitzer; Harris H McIlwain; R Levy; F Wolfe; M Weisman; Q Zeng; B Morrison; James A Bolognese; BC Seidenberg; Barry J Gertz
Effect of specific COX-2 inhibition in osteoarthritis of the knee: a 6 week double blind, placebo controlled pilot study of rofecoxib. Rofecoxib Osteoarthritis Pilot Study Group.
The Journal of rheumatology 1999;26(11):2438-47.
1999: David E Newby; David G Sciberras; C J Ferro; Barry J Gertz; D Sommerville; A Majumdar; R C Lowry; David J Webb
Substance P-induced vasodilatation is mediated by the neurokinin type 1 receptor but does not contribute to basal vascular tone in man.
British journal of clinical pharmacology 1999;48(3):336-44.
1999: M Depré; Anne Van Hecken; Rene Verbesselt; K Wynants; Inge De Lepeleire; A Freeman; S Holland; A Shahane; Barry J Gertz; Paul De Schepper
Effect of multiple doses of montelukast, a CysLT1 receptor antagonist, on digoxin pharmacokinetics in healthy volunteers.
Journal of clinical pharmacology 1999;39(9):941-4.
1999: Keith M Gottesdiener; D R Mehlisch; M Huntington; W Y Yuan; P Brown; Barry J Gertz; S Mills
Efficacy and tolerability of the specific cyclooxygenase-2 inhibitor DFP compared with naproxen sodium in patients with postoperative dental pain.
Clinical therapeutics 1999;21(8):1301-12.
1999: Barbara Knorr; Patrick Larson; HH Nguyen; S Holland; Theodore F Reiss; Paul Chervinsky; K Blake; C H van Nispen; Gertrude Noonan; A Freeman; R Haesen; Nicole Michiels; John D Rogers; RD Amin; Jamie Zhao; Xin Xu; BC Seidenberg; Barry J Gertz; SP Spielberg
Montelukast dose selection in 6- to 14-year-olds: comparison of single-dose pharmacokinetics in children and adults.
Journal of clinical pharmacology 1999;39(8):786-93.
1999: MG Murphy; M A Bach; Diane J Plotkin; James A Bolognese; Jennifer Ng; David Krupa; KA Cerchio; Barry J Gertz
Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. The MK-677 Study Group.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 1999;14(7):1182-8.
1999: Jules I Schwartz; C C Chan; S Mukhopadhyay; K J McBride; T M Jones; S Adcock; C Moritz; J Hedges; K Grasing; D Dobratz; R A Cohen; M H Davidson; K A Bachmann; Barry J Gertz
Cyclooxygenase-2 inhibition by rofecoxib reverses naturally occurring fever in humans.
Clinical pharmacology and therapeutics 1999;65(6):653-60.
1999: Arturo G Porras; Sherry D Holland; Barry J Gertz
Pharmacokinetics of alendronate.
Clinical pharmacokinetics 1999;36(5):315-28.
1999: Anne Van Hecken; M Depré; Rene Verbesselt; K Wynants; Inge De Lepeleire; Jef Arnout; Peggy H Wong; A Freeman; S Holland; Barry J Gertz; Paul De Schepper
Effect of montelukast on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers.
Journal of clinical pharmacology 1999;39(5):495-500.
1999: F Catella-Lawson; BF McAdam; B W Morrison; Shiv Kapoor; D Kujubu; L Antes; K C Lasseter; H Quan; Barry J Gertz; garret fitzgerald
Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids.
The Journal of pharmacology and experimental therapeutics 1999;289(2):735-41.
1999: Veronique Cocquyt; Walter F Kline; Barry J Gertz; Simon Van Belle; Sherry D Holland; M DeSmet; H Quan; Kamlesh P Vyas; KE Zhang; J De Grève; Arturo G Porras
Pharmacokinetics of intravenous alendronate.
Journal of clinical pharmacology 1999;39(4):385-93.
1999: Elliot W Ehrich; aimee dallob; Inge De Lepeleire; Anne Van Hecken; D Riendeau; W Yuan; Arturo G Porras; JM Wittreich; James R Seibold; Paul De Schepper; D R Mehlisch; Barry J Gertz
Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model.
Clinical pharmacology and therapeutics 1999;65(3):336-47.
1999: Rudolph M Navari; Rick R Reinhardt; Richard J Gralla; Mark G Kris; Paul J Hesketh; A Khojasteh; H Kindler; Tobias Grote; Kelly Pendergrass; Steven M Grunberg; Alexandra D Carides; Barry J Gertz
Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group.
The New England journal of medicine 1999;340(3):190-5.
1998: Barry J Gertz; J D Clemens; Sherry D Holland; W Yuan; S Greenspan
Application of a new serum assay for type I collagen cross-linked N-telopeptides: assessment of diurnal changes in bone turnover with and without alendronate treatment.
Calcified tissue international 1998;63(2):102-6.
1998: Johan Svensson; Claes Ohlsson; John-Olov Jansson; G Murphy; D Wyss; David Krupa; KA Cerchio; WJ Polvino; Barry J Gertz; D Baylink; Subburaman Mohan; Bengt-Ake Bengtsson
Treatment with the oral growth hormone secretagogue MK-677 increases markers of bone formation and bone resorption in obese young males.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 1998;13(7):1158-66.
1998: Johan Svensson; Lars Lönn; John-Olov Jansson; G Murphy; D Wyss; David Krupa; KA Cerchio; WJ Polvino; Barry J Gertz; I Boseaus; Lars Sjöström; Bengt-Ake Bengtsson
Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure.
The Journal of clinical endocrinology and metabolism 1998;83(2):362-9.
1998: MG Murphy; L M Plunkett; Barry J Gertz; W He; JM Wittreich; W M Polvino; David R Clemmons
MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism.
The Journal of clinical endocrinology and metabolism 1998;83(2):320-5.
1997: Suresh K Balani; Xin Xu; Vijaya S Pratha; M A Koss; RD Amin; C Dufresne; Randall R Miller; Byron H Arison; George A Doss; M Chiba; A Freeman; Sherry D Holland; Jules I Schwartz; Kenneth C Lasseter; Barry J Gertz; Jon I Isenberg; John D Rogers; Jiunn H Lin; Thomas A Baillie
Metabolic profiles of montelukast sodium (Singulair), a potent cysteinyl leukotriene1 receptor antagonist, in human plasma and bile.
Drug metabolism and disposition: the biological fate of chemicals 1997;25(11):1282-7.
1997: S A Khan; John A Kanis; S Vasikaran; Walter F Kline; B K Matuszewski; Eugene McCloskey; Monique Beneton; Barry J Gertz; David G Sciberras; Sherry D Holland; Jane Orgee; G M Coombes; S R Rogers; Arturo G Porras
Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 1997;12(10):1700-7.
1997: Ian M Chapman; Ora Hirsch Pescovitz; G Murphy; T Treep; KA Cerchio; David Krupa; Barry J Gertz; WJ Polvino; E H Skiles; Suzan S Pezzoli; Michael O Thorner
Oral administration of growth hormone (GH) releasing peptide-mimetic MK-677 stimulates the GH/insulin-like growth factor-I axis in selected GH-deficient adults.
The Journal of clinical endocrinology and metabolism 1997;82(10):3455-63.
1997: David E Newby; David G Sciberras; C M Mendel; Barry J Gertz; Nicholas A Boon; David J Webb
Intra-arterial substance P mediated vasodilatation in the human forearm: pharmacology, reproducibility and tolerability.
British journal of clinical pharmacology 1997;43(5):493-9.
1997: Jules I Schwartz; Wesley Tanaka; D Z Wang; David L Ebel; LA Geissler; aimee dallob; Barry Hafkin; Barry J Gertz
MK-386, an inhibitor of 5alpha-reductase type 1, reduces dihydrotestosterone concentrations in serum and sebum without affecting dihydrotestosterone concentrations in semen.
The Journal of clinical endocrinology and metabolism 1997;82(5):1373-7.
1997: Susan E Kirk; Barry J Gertz; S H Schneider; Mark L Hartman; Suzan S Pezzoli; JM Wittreich; David Krupa; James R Seibold; Michael O Thorner
Effect of obesity and feeding on the growth hormone (GH) response to the GH secretagogue L-692,429 in young men.
The Journal of clinical endocrinology and metabolism 1997;82(4):1154-9.
1997: David G Sciberras; W J Polvino; Barry J Gertz; H Cheng; M Stepanavage; JM Wittreich; T Olah; M Edwards; T Mant
Initial human experience with MK-462 (rizatriptan): a novel 5-HT1D agonist.
British journal of clinical pharmacology 1997;43(1):49-54.
1997: Henry G Bone; Robert Downs; Joseph R Tucci; Steven T Harris; R S Weinstein; A A Licata; Michael R McClung; D B Kimmel; Barry J Gertz; E Hale; W J Polvino
Dose-response relationships for alendronate treatment in osteoporotic elderly women. Alendronate Elderly Osteoporosis Study Centers.
The Journal of clinical endocrinology and metabolism 1997;82(1):265-74.
1996: Jules I Schwartz; Anne Van Hecken; Paul De Schepper; Inge De Lepeleire; K C Lasseter; E C Shamblen; G A Winchell; Marvin Constanzer; C M Chavez; D Z Wang; D L Ebel; S J Justice; Barry J Gertz
Effect of MK-386, a novel inhibitor of type 1 5 alpha-reductase, alone and in combination with finasteride, on serum dihydrotestosterone concentrations in men.
The Journal of clinical endocrinology and metabolism 1996;81(8):2942-7.
1996: H Cheng; Jonathan A Leff; RUHUL AMIN; Barry J Gertz; M De Smet; N Noonan; John D Rogers; W Malbecq; D Meisner; G Somers
Pharmacokinetics, bioavailability, and safety of montelukast sodium (MK-0476) in healthy males and females.
Pharmaceutical research 1996;13(3):445-8.
1995: Barry J Gertz; Sherry D Holland; Walter F Kline; Bogdan K Matuszewski; A Freeman; H Quan; K C Lasseter; J C Mucklow; Arturo G Porras
Studies of the oral bioavailability of alendronate.
Clinical pharmacology and therapeutics 1995;58(3):288-98.
1995: John A Kanis; Barry J Gertz; F Singer; S Ortolani
Rationale for the use of alendronate in osteoporosis.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 1995;5(1):1-13.
1994: JA Aloi; Barry J Gertz; Mark L Hartman; W C Huhn; Suzan S Pezzoli; JM Wittreich; David Krupa; Michael O Thorner
Neuroendocrine responses to a novel growth hormone secretagogue, L-692,429, in healthy older subjects.
The Journal of clinical endocrinology and metabolism 1994;79(4):943-9.
1994: Samuel D Vasikaran; D P O'Doherty; Eugene McCloskey; Barry J Gertz; S Kahn; John A Kanis
The effect of alendronate on renal tubular reabsorption of phosphate.
Bone and mineral 1994;27(1):51-6.
1994: Barry J Gertz; David G Sciberras; L Yogendran; K Christie; K Bador; David Krupa; JM Wittreich; I James
L-692,429, a nonpeptide growth hormone (GH) secretagogue, reverses glucocorticoid suppression of GH secretion.
The Journal of clinical endocrinology and metabolism 1994;79(3):745-9.
1994: Barry J Gertz; P Shao; D A Hanson; H Quan; Steven T Harris; H K Genant; Charles H Chesnut; David R Eyre
Monitoring bone resorption in early postmenopausal women by an immunoassay for cross-linked collagen peptides in urine.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 1994;9(2):135-42.
1993: M G Murphy; B Sytnik; Thomas O G Kovacs; Howard Mertz; D Ewanik; S Shingo; J H Lin; Barry J Gertz; John H Walsh
The gastrin-receptor antagonist L-365,260 inhibits stimulated acid secretion in humans.
Clinical pharmacology and therapeutics 1993;54(5):533-9.
1993: Barry J Gertz; J S Barrett; R Eisenhandler; David Krupa; JM Wittreich; James R Seibold; S H Schneider
Growth hormone response in man to L-692,429, a novel nonpeptide mimic of growth hormone-releasing peptide-6.
The Journal of clinical endocrinology and metabolism 1993;77(5):1393-7.
1993: S R Nussbaum; R P Warrell; R Rude; J Glusman; J P Bilezikian; A F Stewart; M Stepanavage; J F Sacco; S D Averbuch; Barry J Gertz
Dose-response study of alendronate sodium for the treatment of cancer-associated hypercalcemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(8):1618-23.
1993: Steven T Harris; Barry J Gertz; Harry K Genant; D R Eyre; T T Survill; J N Ventura; J DeBrock; E Ricerca; Charles H Chesnut
The effect of short term treatment with alendronate on vertebral density and biochemical markers of bone remodeling in early postmenopausal women.
The Journal of clinical endocrinology and metabolism 1993;76(6):1399-406.
1993: Barry J Gertz; Sherry D Holland; Walter F Kline; Bogdan K Matuszewski; Arturo G Porras
Clinical pharmacology of alendronate sodium.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 1993;3 Suppl 3():S13-6.
1992: D P O'Doherty; Barry J Gertz; Wendy B Tindale; David G Sciberras; T T Survill; John A Kanis
Effects of five daily 1 h infusions of alendronate in Paget's disease of bone.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 1992;7(1):81-7.
1991: F J Ortiz-Alonso; William H Herman; Barry J Gertz; V C Williams; Marla J Smith; Jeffrey B Halter
Effect of an oral alpha 2-adrenergic blocker (MK-912) on pancreatic islet function in non-insulin-dependent diabetes mellitus.
Metabolism: clinical and experimental 1991;40(11):1160-7.
1990: Owen Wolkowitz; Barry J Gertz; H Weingartner; L Beccaria; K Thompson; R A Liddle
Hunger in humans induced by MK-329, a specific peripheral-type cholecystokinin receptor antagonist.
Biological psychiatry 1990;28(2):169-73.
1990: R A Liddle; Barry J Gertz; S Kanayama; L Beccaria; T W Gettys; I L Taylor; R J Rushakoff; V C Williams; L D Coker
Regulation of pancreatic endocrine function by cholecystokinin: studies with MK-329, a nonpeptide cholecystokinin receptor antagonist.
The Journal of clinical endocrinology and metabolism 1990;70(5):1312-8.
1989: Barry J Gertz; P H Vlasses; M L Rocci; L D Coker; V Williams; T D Bjornsson; K H Jones
Clinical evaluation of a benzofuroquinolizine alpha 2-adrenoceptor antagonist.
Clinical pharmacology and therapeutics 1989;46(5):566-75.
1989: R A Liddle; Barry J Gertz; S Kanayama; L Beccaria; L D Coker; T A Turnbull; E T Morita
Effects of a novel cholecystokinin (CCK) receptor antagonist, MK-329, on gallbladder contraction and gastric emptying in humans. Implications for the physiology of CCK.
The Journal of clinical investigation 1989;84(4):1220-5.
1989: John Bowen Warren; C T Dollery; R W Fuller; V C Williams; Barry J Gertz
Assessment of MK-912, an alpha 2-adrenoceptor antagonist, with use of intravenous clonidine.
Clinical pharmacology and therapeutics 1989;46(1):103-9.
1988: David G Gardner; Barry J Gertz; Christian Deschepper; D Y Kim
Gene for the rat atrial natriuretic peptide is regulated by glucocorticoids in vitro.
The Journal of clinical investigation 1988;82(4):1275-81.